Cholesterol drug inhibits cancer cells in lab

	Tweet

Atorvastatin, the widely prescribed cholesterol-lowering “statin” drug, sold under the trade name Lipitor, shows significant action against human bladder cancer cells in laboratory experiments, researchers report in the medical journal Urology.

Although the findings suggest that atorvastatin is active against bladder cancer cells, clinical trials are still needed to confirm these results in patients, lead investigator Dr. Ashish M. Kamat told Reuters Health.

Kamat and Dr. Gina M. Nelkin of the University of Texas, M. D. Anderson Cancer Center in Houston, note that some research has suggested that statin use might increase the risk of cancer-related deaths.

To further investigate the effects of atorvastatin, the researchers examined the activity of this cholesterol-lowering drug on two types of cultured human bladder cancer cells. At concentrations comparable to those achievable with oral administration, atorvastatin inhibited cell growth and DNA synthesis in both bladder cancer cell types.

This led to significant cell toxicity, which was demonstrated by DNA fragmentation and induction of cell death. Destruction of up to 70 percent of bladder cancer cells was observed.

The safety of this drug has already been established Dr. Kamat pointed out. Based on these new observations, he recommends that studies be done to evaluate the cancer prevention capabilities of atorvastatin. “At the least, it might offer patients, who are often older and smokers, protection against cardiac events.”

SOURCE: Urology, December 2005.

RELATED STORIES:
Sales jobs tied to bladder cancer risk   Researcher Says Improved Detection of Bladder Tumors Reduces Cancer Recurrence   New treatment option studied for bladder cancer   Urinary tract cancer associated with Chinese herbal products containing aristolochic acid   Chemicals in meat may be linked to bladder cancer   Delaying bladder cancer surgery increases mortality   Women in nursing homes often have bladder problems   Bladder cancer: Need for a standardized protocol of management   MDCT Shows Potential for Detecting Bladder Cancer Without Surgery or Contrast   Less bladder cancer in frequent painkiller users   Patients unaware of link between smoking and bladder cancer   Measurement of Urinary Protein Can Help Detect Recurrent Bladder Cancer   Variation in prostate stem cell antigen gene raises bladder cancer risk   Estrogen use tied to bladder control problems   New made-in-Canada therapy for bladder cancer shows promising results   AUA releases new guidelines on non-muscle invasive bladder cancer   Home urine testing cuts bladder cancer deaths   Bladder cancer: A difficult problem?   New Bladder Cancer Therapy for Patients Unresponsive to Standard Treatment   Arsenic cancer risk still high decades later in Chile region   Certain Ecologic Factors Associated with Greater Risk of Bladder Cancer   Early menopause related to bladder cancer risk

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]